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Psychological and Genetic Predictors of Pain Tolerance
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Eric M. Snyder5,a and Jason H. Karnes2,a,*
Previous studies have shown associations between genetic polymorphisms and pain tolerance, but psychological evalua-
tions are seldom measured. The objective of this study was to determine the independent effects of demographic, psycho-
logical, and genetic predictors of cold noxious pain tolerance. Healthy subjects (n = 89) completed the Pain Catastrophizing 
Scale (PCS) and Fear of Pain Questionnaire (FPQ- III), underwent genotyping for candidate single nucleotide polymorphisms 
(SNPs), and completed a cold- pressor test in a 1–2°C water bath for a maximum of 3 minutes. The primary outcome measure 
was pain tolerance, defined as the maximum duration of time subjects left their nondominant hand in the cold- water bath. 
Cox proportional hazards regression indicated that female sex, Asian race, and increasing PCS and FPQ- III scores were as-
sociated with lower pain tolerance. No candidate SNP was significantly associated with pain tolerance. Future genetic stud-
ies should include demographic and psychological variables as confounders in experimental pain models.
Interindividual variability of pain perception is not completely 
understood. Such variation is likely influenced by a combina-
tion of complex environmental and biological factors. Previous 
studies have shown modest heritability of pain tolerance and 
identified genetic polymorphisms explaining some of this vari-
ability.1–3 Variants of certain genes encoding target structures 
within the nociceptive pathway may result in an attenuation or 
augmentation of specific types of pain. Genetic variation en-
coding receptors related to temperature sensation have been 
previously shown to contribute to cold pain sensitivity.4–11
Genes containing associated variants include the transient 
receptor potential A subtype 1 gene (TRPA1), the catechol- 
o- methyltransferase gene (COMT), and the fatty acid amide 
hydrolase gene (FAAH).4,6,12–15 TRPA1 is an ion channel that 
belongs to a family of transient receptor potential channels, 
which respond to various sensory stimuli such as pain, and 
the variant rs11988795 G>A in TRPA1 is known to enhance 
cold pain perception.12,16 COMT is an enzyme involved in 
catecholamine metabolism, influencing concentrations of do-
pamine and norepinephrine in the brain and affecting mood 
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Study Highlights
WHAT IS THE CURRENT KNOWLEDGE ON THE TOPIC?
✔ Experimental pain models in humans have shown po-
tential associations between genetic polymorphisms and 
pain measures, but associations between genetic variants 
and pain tolerance have not been replicated.
Genetic studies simultaneously measure psychological 
factors, which can also influence sensitivity or confound 
the relationship between genetic polymorphisms, and pain 
measurement.
WHAT QUESTION DID THIS STUDY ADDRESS?
✔ The objective of this study was to determine the asso-
ciation between demographics, psychological survey data, 
and selected single nucleotide polymorphisms in TRPA1, 
COMT, and FAAH genes on tolerance to cold noxious pain 
using an experimental pain model.
WHAT DOES THIS STUDY ADD TO OUR KNOWLEDGE?
✔ Our study was unable to find a relationship between 
TRPA1, COMT, and FAAH polymorphisms and inter indi-
vidual variability in tolerance to cold noxious pain.
Our study highlights the contribution of demographic and 
psychological variables to pain sensitivity.
HOW MIGHT THIS CHANGE CLINICAL PHARMACOLOGY 
OR TRANSLATIONAL SCIENCE?
✔ The results of this article suggest that experimental and 
translational pain models evaluating genetic influences on 
pain should include demographic and detailed psycholog-
ical measures.
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and mental processes, such as pain perception and catastro-
phization. Several polymorphisms in COMT, including rs6269 
and rs4646312, have been associated with variability in pain 
sensitivity and perception.6,17 FAAH, an enzyme that cata-
lyzes the formation of arachidonic acid, regulates fatty acid 
amide catabolism in the nervous system, which can influence 
response to pain. FAAH is known to be a key regulator in me-
tabolism of anandamide, a weak cannabinoid receptor activa-
tor.18 FAAH polymorphisms, including rs2295633, rs4141964, 
and rs932816, have also been shown to affect pain perception 
and susceptibility in experimental pain models.14,19 Variation 
in these genes, which are important nodes in nociceptive and 
pharmacogenetic pathways, are likely important for develop-
ment of translational pain prediction models due to the previ-
ously observed impact on human experimental pain tolerance.
In addition to genetic polymorphisms, patient demograph-
ics and psychological factors have a strong influence on pain 
experiences.1,3,20,21 Differences in patient perceptions of pain 
have been observed according to demographic factors, in-
cluding patient race and gender.22–24 The effect of genetic vari-
ants on pain is confounded by these other important factors, 
which are often not measured in genetic and pharmacogenetic 
studies.4–11 The independent effect of genetic variation on the 
physiological response to pain and their contribution to per-
ception of pain is understudied. Validated scales that measure 
psychological factors influencing pain perception are available 
and include the Pain Catastrophizing Scale (PCS) and the Fear 
of Pain Questionnaire- III (FPQ- III).25,26 Catastrophizing involves 
an exaggerated negative orientation toward noxious stimuli 
and has been associated with greater pain intensity during 
experimental pain models.3,25,27 Similarly, the measurement 
of pain- related fear using the FPQ- III was predictive of exper-
imental pain.26,27 These scales provide important information 
that could be incorporated into pain models that estimate ge-
netic influences. However, studies using similar experimental 
pain models often evaluate genetic influences in isolation, with-
out considering these important psychological factors.
The objective of this study was to determine the asso-
ciation between demographics, psychological status, and 
selected genetic variants on tolerance to cold noxious pain 
using an experimental pain model. The intent was to deter-
mine the relative contribution of each factor by measuring 
all pertinent predictors in a single experimental pain model.
METHODS
Experimental design and subject selection
The present investigation was a cross- sectional study 
conducted in a clinical research laboratory. The study was 
approved by the University of Arizona’s Human Subject 
Protection Program prior to initiation and subject enrollment. 
Subjects were recruited using advertisements posted on 
bulletin boards on the University’s health sciences campus 
and via word of mouth. Interested subjects were asked to 
contact a research coordinator to schedule an initial screen-
ing for eligibility and participation in the study. Inclusion cri-
teria were the following: subjects had to be able to consent 
on their own and be over 18 years of age. Exclusion criteria 
were: subjects could not have a history of syncope, cardio-
vascular disease, pulmonary disease, vascular conditions, 
renal disease, chronic pain, or taking pain medications.
Study protocol and data collection
Subjects were first screened and, if eligible, consent was 
obtained for study participation. Demographic information 
was obtained and subjects were measured for height and 
weight. The experiment consisted of three phases: (i) com-
pletion of written surveys; (ii) buccal swabs for genetic anal-
yses; and (iii) a cold- pressor test. Each phase is described 
below. The entire visit was estimated to take no more than 
1 hour.
Written surveys. The subjects completed two experimentally 
validated surveys: the PCS25 and the FPQ- III.26 After a brief 
explanation by the research staff, the subjects completed 
the surveys in writing individually. The research staff did 
not administer the surveys or obtain responses verbally. 
The PCS consists of 13 questions, which are rated by the 
subjects on a five- point scale. The PCS consists of three 
domains: rumination, magnification, and helplessness. For 
this study, the sum total score of all domains was used for 
analyses, as previously described and validated.25,28,29 The 
total score on the PCS can range from 0−52. A higher score 
indicates a greater degree of catastrophizing.
The FPQ- III consists of 30 questions, which are also rated 
by the subjects on a five- point scale. This questionnaire as-
sesses pain- related fear of the subjects. The questionnaire is 
totaled to obtain a score of 30–150. A higher score indicates 
greater fear related to pain. The FPQ- III does not have specific 
domains or categories. The total score was used for analyses. 
For both surveys, subjects were also dichotomized at the me-
dian into high and low fear groups to visually examine differ-
ences between the two groups in the survival analysis.
Genetic analyses. Following the surveys, two buccal 
swabs using a buccal brush were taken for DNA extraction 
and genetic analysis. The University of Arizona Genetics 
Core facility provided the brush and collection vials and 
performed genetic analysis. DNA quantification was 
performed using PicoGreen (Thermo Fisher Scientific, 
Waltham, MA). Prevalidated primers and probe sets for 
TaqMan Allelic Discrimination Assay were obtained (Thermo 
Fisher Scientific, Waltham, MA). Custom primers and 
probe sets for TaqMan Allelic Discrimination Assay were 
generated via Life Technologies File Builder 3.1 software for 
genotyping. Reactions were run at 10 μL, containing TaqMan 
Universal PCR Master Mix, No AmpEraseR UNG (Thermo 
Fisher Scientific, Waltham, MA), 10 ng total DNA, and 1 × 
Assay Mix. All samples were processed and analyzed on 
the 7900 Real- Time PCR System (Thermo Fisher Scientific, 
Waltham, MA) with cycling conditions (95°C for 10 minutes, 
50 cycles of 92°C for 15 seconds, and 60°C for 1 minute) 
and Genotyper software (SDS system, version 2.3). Single 
nucleotide polymorphisms (SNPs) within the following 
genes were evaluated: TRPA1 (rs11988795), COMT 
(rs4646312, rs6269), and FAAH (rs932816, rs4141964, and 
rs2295633). Based on previous literature, these six SNPs 
were considered to be most likely to have an effect on pain 
perception, using a cold- pressor test.4,12,16 To ensure quality 
control of genotype data, SNP genotypes were only used in 
statistical models if the SNP call rate was > 95% and SNPs 
were within Hardy-Weinberg equilibrium (P > 0.05).
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Cold- pressor test. After the buccal swabs, subjects 
completed a cold- pressor test while seated. A cold- pressor 
test was used in order to test replication of existing literature.4 
The cold-pressor test has a robust literature supporting its use. 
In addition, the cold-pressor test is easily and inexpensively 
implemented, safe, and standardized.30 The cold- pressor test 
apparatus consisted of a 4-L circulating water bath, which was 
maintained between 1 and 2°C. The water in the beaker was 
stirred continuously with a magnetic stirring rod to maintain a 
uniform temperature. The subjects were instructed to insert 
their nondominant hands into the water bath. Although use 
of the dominant vs. nondominant hand is not expected to 
affect results, the nondominant hand was used in all subjects 
to retain consistency in the procedure and reflect the most 
common approach from the literature.30,31
The hand was inserted up to 5 cm above the wrist, 
which was confirmed visually. Subjects were instructed to 
leave their hand in the water bath for as long as they could. 
However, the maximum duration was set at 3 minutes at 
which time they were instructed to remove their hand. 
Subjects were blinded to this maximum limit. Pain was 
measured on a verbal numeric rating scale of 0–10 (0 being 
no pain and 10 being the worst possible pain). Time values 
were measured using a digital stopwatch and recorded in 
seconds. The following measurements were taken: (i) pain 
threshold – time in seconds from hand insertion to a pain 
score of one or more; (ii) pain tolerance – time in seconds 
from hand insertion to the time subject voluntarily removes 
hand; (iii) pain score every 30 seconds; and (iv) pain score at 
time of removal of hand from water.
Statistical analyses
The primary outcome measured was pain tolerance. 
Continuous variables such as age, body mass index (BMI), 
survey scores, pain scores, pain tolerance, and pain thresh-
old were summarized and reported as means and SDs. 
Categorical variables, such as sex and race, were reported 
as percentages. Differences between demographic vari-
ables according to subjects who did and did not complete 
the cold-pressor test were calculated using t- tests and χ2 
tests as appropriate. PCS score was dichotomized at the 
median, and patients were classified as catastrophizers 
(higher scores) and noncatastrophizers (lower scores). 
Similarly, the FPQ- III was dichotomized at the median, and 
patients were categorized as high fear (higher scores) or 
low fear (lower values). The primary outcome variable was 
censored at 180 seconds, thus, a survival analysis with Cox 
proportional hazards regression was conducted. Hazards 
ratios (HRs) were reported for variables that could be asso-
ciated with the outcome. These were age, sex, race, BMI, 
PCS score, FPQ- III score, and SNPs. The HR for the FPQ- III 
represents a 25- point change on the scale. This is an ~20% 
change in score on this scale. PCS and FPQ- III scores were 
dichotomized at the median and Kaplan- Meier curves were 
used to visualize differences in pain tolerance. Log- rank 
tests were also used to assess differences in pain tolerance 
between dichotomized groups. SNP influences on pain toler-
ance were tested in an additive model adjusted for sex, race, 
and total PCS score. In a sensitivity analysis, SNP influences 
on pain tolerance were also tested in an additive model ad-
justed for sex, race, and FPQ- III score. A polygenic risk score 
consisting of the combined number of variant alleles for all 
SNPs was also tested for association with the primary out-
come. An alpha of 0.05 was used for all analyses. In order to 
achieve 80% power at α = 0.05 and an effect of 12% of the 
variance explained in the multivariate regression model, we 
required 84 subjects to determine a significant effect of PCS 
score on an individual’s pain sensitivity. Analyses were con-
ducted in STATA 13 (College Station, TX) and R version 3.4.3.
RESULTS
There were 89 subjects who completed the study. The mean 
age of subjects was 26 ± 7 years, and 58% were women. 
Table 1 Demographic data among subjects who completed and did not complete the cold-pressor test
Variablea Did not complete cold- pressor test (n = 46)b Completed cold- pressor test (n = 43)b P valuec
Age, years 27.54 (8.11) 26.19 (5.49) 0.361
Female, n (%) 33 (71.7) 19 (44.2) 0.016
BMI, kg/m2 24.67 (5.60) 25.82 (5.82) 0.348
Race, n (%) 0.031
Asian 17 (37.0) 6 (14.0)
Hispanic 6 (13.0) 6 (14.0)
Other 6 (13.0) 3 (7.0)
White 17 (37.0) 28 (65.1)
PCS score 17.33 (9.73) 10.19 (6.91) < 0.001
Rumination 7.30 (4.05) 4.47 (3.2) < 0.001
Magnification 3.61 (2.58) 2.16 (1.53) 0.002
Helplessness 6.41 (4.34) 3.56 (3.48) 0.001
FPQ- III score 78.91 (22.65) 69.18 (17.93) 0.028
Pain threshold, seconds 8.30 (6.86) 9.88 (6.30) 0.262
Pain tolerance, seconds 64.80 (45.47) 180.00 (0.00) < 0.001
BMI, body mass index; FPQ- III, Fear of Pain Questionnaire- III; PCS, Pain Catastrophizing Scale.
aValues are mean and SD unless otherwise noted. bSubjects who did not complete cold- pressor test removed their hand before the 3- minute mark. Subjects 
who completed the cold- pressor test did not remove their hand before the 3- minute maximum time. cP values are calculated using t- tests and χ2 tests as 
appropriate.
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The most common race/ethnicity was white (n = 45, 51%), 
followed by Asian (n = 23, 26%), Hispanic (n = 12, 14%), 
and other (n = 9, 10%). The mean BMI was 25 ± 6 kg/m2. 
The mean total PCS score was 14 ± 9 and the mean FPQ- III 
score was 74 ± 21. Demographic data, survey scores, and 
results of the cold- pressor test among subjects who com-
pleted and did not complete the cold pressor test are pre-
sented in Table 1. Factors associated with completing the 
maximum duration of the cold- pressor test were male sex, 
white race, and lower PCS and FPQ- III scores. During the 
cold- pressor test, the mean pain threshold was 9 ± 7 sec-
onds, and mean pain tolerance was 120 ± 66 seconds. Pain 
scores measured at 30, 60, 90, 120, 150, and 180 seconds 
were 4.8 ± 2.1 (n = 78), 6.0 ± 2.1 (n = 63), 5.9 ± 2.0 (n = 53), 
5.8 ± 2.2 (n = 51), 5.8 ± 2.2 (n = 47), and 5.9 ± 2.5 (n = 43), 
respectively. The final pain score at time of hand removal 
was 7.0 ± 2.3.
In survival analyses, age and BMI were not significantly as-
sociated with pain tolerance, whereas women were observed 
to have lower pain tolerance than men (Table 2). Asians were 
observed to be more likely to remove their hands more quickly 
(lower pain tolerance) compared with whites. Increasing PCS 
and FPQ- III scores were also associated with decreased pain 
tolerance. After adjusting for sex and race, PCS score (HR, 
1.1 (1.0−1.1), P = 3.35 × 10−4) and FPQ- III score (HR, 1.6 
(1.1–2.4), P = 0.009) were significantly associated with pain 
tolerance. Although all three domains of the PCS score (rumi-
nation, magnification, and helplessness) were independently 
associated with pain tolerance, rumination was more 
strongly associated the other two domains (HR, 1.2 (1.1–1.3), 
P = 2.9 × 10−4). An increasing HR represents lower pain toler-
ance (i.e., increased hazard of hand removal), and the HR for 
FPQ- III represented a 25- point change on the scale.
The differences between dichotomized groups in terms of 
pain tolerance were visualized using Kaplan- Meier curves. 
Catastrophizers remove their hand significantly more 
quickly from the cold water bath (log- rank P = 4.12 × 10−5; 
Figure 1). Subjects with high fear were also more likely to 
remove their hand from the cold water bath more quickly 
(log- rank P = 0.028; Figure 2). No statistically significant as-
sociations were observed between investigated SNPs and 
pain tolerance after adjustment for gender, race, and PCS 
score (Table 3). In the sensitivity analysis, no SNPs were 
associated with pain tolerance after adjustment for gender, 
race, and FPQ- III score. The polygenic risk score, indicating 
the combined number of variant alleles for all SNPs, was 
also not associated with pain tolerance (HR, 1.02 (0.68–
1.52), P = 0.93).
DISCUSSION
The key finding in this study was that demographic and psy-
chological factors were associated with tolerance to pain. 
These results replicate findings from previous studies evalu-
ating the influence of PCS and FPQ- III on pain tolerance and 
perception.25–27 The effect size for these scales was relatively 
large with a doubling of the hazard for hand removal for a 
Figure 1 Kaplan- Meier survival estimates by catastrophization category. The Pain Catastrophizing Scale score was dichotomized at 
the median, and patients were classified as catastrophizers (higher scores) and noncatastrophizers (lower scores). Survival time is pain 
tolerance, as indicated by the duration of time in seconds that subjects were able to retain their hand in the water bath.
Table 2 Effects of demographic variables and survey responses on 
pain tolerance
Variable HRa 95% CIa P valuea
Age, years 1.0 1.0–1.1 0.369
Sex, male 0.4 0.2–0.7 0.003
BMI, kg/m2 1.0 0.9–1.0 0.218
Race
White Reference – –
Asian 3.1 1.6–6.1 0.001
Hispanic 1.6 0.6–4.1 0.322
Other 2.5 1.0–6.4 0.051
PCS scoreb 1.1 1.0–1.1 3.35 × 10−4
Rumination 1.2 1.1–1.3 2.9 × 10−4
Magnification 1.2 1.0–1.3 0.012
Helplessness 1.14 1.1–1.2 7.2 × 10−4
FPQ- III scorec 1.6 1.1–2.4 0.009
BMI, body mass index; CI, confidence interval; FPQ- III, Fear of Pain 
Questionnaire- III; HR, hazard ratio; PCS, Pain Catastrophizing Scale.
aHRs, 95% CIs, and P values were calculated with Cox proportional haz-
ards regression conducted with the primary outcome variable censored at 
180 seconds. Analyses for age, sex, race, and BMI are unadjusted. bAnaly-
ses for PCS score is adjusted for sex and race. PCS score and domains of 
the PCS score represent one- point change on the scale. cAnalysis for FPQ- 
III score is adjusted for sex and race. The HR for the FPQ- III represents a 
25- point change on the scale.
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20% increase in pain- related fear or catastrophization. This 
remained true after adjusting for covariates, such as sex and 
race, which was also observed to contribute to pain toler-
ance. We did not replicate previously published findings re-
lated to SNPs in TRPA1, COMT, or FAAH and their influence 
on pain tolerance. Our study suggests that tools to assess 
psychological aspects of pain, such as the PCS and FPQ- 
III, are important in predicting pain tolerance. These results 
might have important implications for the potential use of 
such translational tools in the clinical setting, as in preoper-
ative assessment to predict postoperative pain and in pre-
dicting the pharmacogenetic impact of SNPs on analgesic 
response. Similarly, these tools could be studied in patients 
during admission to the hospital or triage in emergency de-
partments to guide therapy or understand patient perception 
of their pain. For instance, catastrophizing has been shown 
to lead to delayed recovery in some pain states.32
Our findings did not replicate the observed associations 
from previous investigations implicating polymorphisms in 
TRPA1, COMT, and FAAH in pain tolerance.4,6,12–15 These 
SNPs were selected based on previous associations with 
pain sensitivity in similar experimental models and their 
mechanistic role in nociceptive pathways.4,6,12–15 Kim et al.4 
identified multiple SNPs that were associated with pain 
sensitivity in 735 healthy subjects. The discrepancy be-
tween previous results and the present study may be due 
to the limited sample size of our cohort or to the distinct 
demographic characteristics of our cohort, which included 
younger subjects with a high proportion of Asian race. In 
addition, psychological confounders, which were not mea-
sured, may have contributed to pain sensitivity. Our findings 
are consistent with previous investigations of influence of 
psychological and demographic variables on genetic asso-
ciations with pain tolerance.21,33 Our study adds to existing 
evidence suggesting that psychological and demographic 
variables are critical elements of translational pain models, 
including predictive models of pain responses to analgesic 
treatment. This study might also be informative for studies of 
pain response during analgesic treatment. Future studies of 
pain in many contexts, including drug response, may bene-
fit from thorough investigation of baseline demographic and 
psychological variables.
The study population primarily included students. 
Therefore, the demographics of the subjects reflected that of 
students in the college. The majority of the subjects were fe-
male, and a large proportion was Asian. Both of these factors 
were associated with decreased pain tolerance in our study. 
Sex- related differences in experimental pain sensitivity are 
Figure 2 Kaplan- Meier survival estimates by fear of pain category. The results of the Fear of Pain Questionnaire- III was dichotomized 
at the median, and patients were categorized as high fear (higher scores) or low fear (lower values). Survival time is pain tolerance, as 
indicated by the duration of time in seconds that subjects were able to retain their hand in the water bath.
Table 3 Effect of single nucleotide polymorphisms on pain tolerance
SNP Gene Allele MAF
MAF 








HR (95% CI) c
Adjusted 
P valuec
rs4646312 COMT C 0.31 0.43 0.37 0.15 0.581 0.76 (0.48–1.24) 0.279 1.29 (0.75–2.22) 0.364
rs6269 COMT G 0.31 0.44 0.37 0.36 0.756 0.78 (0.49–1.24) 0.297 1.27 (0.76–2.14) 0.364
rs2295633 FAAH A 0.33 0.34 0.15 0.62 0.845 0.99 (0.63–1.54) 0.952 1.30 (0.78–2.16) 0.317
rs4141964 FAAH T 0.43 0.34 0.45 0.74 0.956 1.19 (0.80–1.77) 0.379 1.27 (0.79–2.03) 0.320
rs932816 FAAH A 0.19 0.32 0.02 0.13 0.250 0.60 (0.33–1.11) 0.104 0.693 (0.34–1.40) 0.309
rs11988795 TRPA1 T 0.41 0.26 0.56 0.38 0.485 1.33 (0.86–2.07) 0.204 1.67 (0.96–2.88) 0.067
95% CI, 95% confidence interval; CEU, Utah residents with Northern and Western European ancestry in the 1000 Genomes project; CHB, Han Chinese in 
the 1000 Genomes project; COMT, catechol- o- methyltransferase; FAAH, fatty acid amide hydrolase; HR, hazard ratio; HWE, Hardy- Weinberg equilibrium; 
MAF, minor allele frequency; SNP, single nucleotide polymorphism; TRPA1, transient receptor potential A subtype 1; YRI, Yorubans from Ibadan, Nigeria in 
the 1000 Genomes project.
aMinor allele frequencies acquired from the 1000 Genomes project acquired from grch37.ensembl.org. bHRs, 95% CIs, and P values were calculated with 
Cox proportional hazards regression conducted with the primary outcome variable censored at 180 seconds. cHRs, 95% CIs, and P values were calculated 
with Cox proportional hazards regression conducted with the primary outcome variable censored at 180 seconds. Adjusted SNP analyses are adjusted for 
sex, race, and Pain Catastrophizing Scale score.
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known and previous studies have also shown increased pain 
sensitivity in Asians compared with whites.34,35 We did not 
find an association between age and tolerance to pain. In a 
previous investigation, older adults had decreased sensitiv-
ity to heat but not cold stimuli compared with middle- aged 
adults.36 In our study, the mean age was 26 years, preclud-
ing our ability to make conclusions regarding effects of age 
on pain tolerance.
There are several limitations that are worthy of mention 
in this study. Our sample size may not have been large 
enough to find differences in pain tolerance between gen-
otypes. In addition, our study was restricted to a relatively 
small number of SNPs with putative roles in pain toler-
ance. Our observations are also based on pain tolerance 
only as assessed by the cold- pressor test. Additional 
SNPs have been associated with pain tolerance and might 
be included in more comprehensive investigations of ge-
nomic influences on pain tolerance.5,11,37 Specifically, en-
dogenous opioid receptors likely play a key role in pain 
sensitivity and inclusion of variation in the opioid receptor 
mu 1 gene (OPRM1) and the opioid receptor kappa 1 gene 
(OPRK1) would be informative in future studies.6 Several 
SNPs have also been shown to influence pain tolerance in 
a drug- dependent manner, and these polymorphisms may 
impact baseline pain perception.8–10,38,39 Notably, the vast 
majority of these studies did not evaluate psychological 
indices of pain. As previously mentioned, we were unable 
to assess the effects of age on pain tolerance. We did 
find significant associations between pain tolerance and 
variables, such as sex, race, PCS, and FPQ- III, excluding 
the possibility of a type II error for these demographic and 
psychological variables.
In conclusion, our study identified female gender, Asian 
race, catastrophizing, and fear of pain as risk factors for de-
creased tolerance to pain. Our results highlight the relative 
contribution of demographic and psychological variables to 
pain sensitivity. Our results suggest that future genetic and 
pharmacogenetic studies should include demographics and 
psychological factors as confounders in experimental and 
clinical pain models.
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